Plaque Psoriasis
Plaque psoriasis is a chronic autoimmune condition that causes the rapid growth of skin cells, leading to thick, red, scaly patches on the skin, often accompanied by itching and discomfort.
Bimekizumab for Children with Moderate to Severe Plaque Psoriasis
We are studying how well bimekizumab works compared to ustekinumab in children and teens aged 6 to under 18 with moderate to severe plaque psoriasis. The trial will also look at safety and quality of life improvements.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 6 and 17 years old?
- Have you been diagnosed with moderate to severe plaque psoriasis for at least 3 months?
- Is at least 10% of your body affected by psoriasis?
- Have you had any serious infections or a history of active tuberculosis?
- Have you been diagnosed with severe depression in the past 6 months?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Cliniques Universitaires Saint-Luc
#40121: Dermatology
Sint-Stevens-Woluwe, Belgium
Centre hospitalier universitaire de Liege
#40420: Dermatology
Tilff, Belgium
Fakultni Nemocnice Plzen
#40748: Dermatology
Pilsen, Czechia
Sponsor: UCB Biopharma
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.